(R)-3-((4-(thiazol-2-ylmethyl)morpholin-2-yl)methyl)-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine

ID: ALA5169811

Cas Number: 1305115-80-3

PubChem CID: 52938379

Product Number: P612731, Order Now?

Max Phase: Preclinical

Molecular Formula: C14H15F3N8OS

Molecular Weight: 400.39

Names and Identifiers

Canonical SMILES:  Nc1nc(C(F)(F)F)nc2c1nnn2C[C@H]1CN(Cc2nccs2)CCO1

Standard InChI:  InChI=1S/C14H15F3N8OS/c15-14(16,17)13-20-11(18)10-12(21-13)25(23-22-10)6-8-5-24(2-3-26-8)7-9-19-1-4-27-9/h1,4,8H,2-3,5-7H2,(H2,18,20,21)/t8-/m1/s1

Standard InChI Key:  VNLPYEMGHGDRRZ-MRVPVSSYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   -2.5176    1.8220    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8030    2.2343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0911    1.8225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0911    0.9972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8012    0.5855    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5176    0.9935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3064    0.7423    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3064    2.0774    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1785    1.4097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8030    3.0596    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0927   -0.0547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7040   -0.2683    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2323    0.5810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2323   -0.2441    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6455    1.2969    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0582    0.5810    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.2876    0.3151    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0847    0.1015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2982   -0.6954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7148   -1.2789    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9177   -1.0653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9284   -2.0760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7255   -2.2896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3664   -1.7706    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0582   -2.2197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8447   -3.0164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0210   -3.0596    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  4  7  1  0
  3  8  1  0
  8  9  2  0
  9  7  1  0
  2 10  1  0
  7 11  1  0
 12 11  1  6
  6 13  1  0
 13 14  1  0
 13 15  1  0
 13 16  1  0
 17 12  1  0
 18 17  1  0
 19 18  1  0
 20 19  1  0
 21 20  1  0
 12 21  1  0
 20 22  1  0
 22 23  1  0
 24 23  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5169811

   PF-04957325

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 400.39

Molecular Weight (Monoisotopic): 400.1042

AlogP: 1.18

#Rotatable Bonds: 4

Polar Surface Area: 107.87

Molecular Species: NEUTRAL

HBA: 10

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 5.23

CX LogP: 1.39

CX LogD: 1.38

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.70

Np Likeness Score: -2.18

References

1. Xi M, Sun T, Chai S, Xie M, Chen S, Deng L, Du K, Shen R, Sun H..  (2022)  Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,  232  [PMID:35144038] [10.1016/j.ejmech.2022.114170]

2. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE..  (2021)  The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,  212  [PMID:33412421] [10.1016/j.ejmech.2020.113123]

3. Sun J, Xiao Z, Haider A, Gebhard C, Xu H, Luo HB, Zhang HT, Josephson L, Wang L, Liang SH..  (2021)  Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.,  64  (11.0): [PMID:34042442] [10.1021/acs.jmedchem.1c00115]

Source

Source(1):

• Scientific Literature